Summary
Eli Lilly and Company (LLY) announced changes to its Board of Directors via an 8-K filing on November 19, 2024. The most significant development for investors is the appointment of Jon Moeller, the current Chairman, President, and CEO of Procter & Gamble, as a new independent director to the LLY Board, effective December 1, 2024. Mr. Moeller brings extensive experience from over two decades in finance, business, and strategy at P&G and will serve on the Audit Committee and the Directors and Corporate Governance Committee. Concurrently, the filing notes the resignation of Karen Walker from the Board, effective December 31, 2024. Ms. Walker, who has served since 2018, is expected to collaborate with the Company on digital commercial activities starting in 2025. Her resignation is confirmed not to be due to any disagreements regarding the Company's operations, policies, or practices. These board changes signal a strategic enrichment of the board's expertise with Mr. Moeller's appointment.
Key Highlights
- 1Jon Moeller, Chairman, President & CEO of Procter & Gamble, appointed as a new independent director to Eli Lilly's Board, effective December 1, 2024.
- 2Mr. Moeller will serve on the Board's Audit Committee and Directors and Corporate Governance Committee.
- 3Karen Walker has resigned from the Board, effective December 31, 2024.
- 4Ms. Walker's resignation is stated to be without disagreement regarding the Company's operations, policies, or practices.
- 5Ms. Walker is expected to engage with Eli Lilly on digital commercial activities starting in 2025.
- 6The appointment of Mr. Moeller is expected to enhance the Board's strategic and operational oversight.